EnteroBiotix newsroom

Filter news by category

News & press releases

News
EnteroBiotix Announces First Patient Dosed in Phase 2b RISE Study of EBX-102-02 in Irritable Bowel Syndrome with Constipation
EnteroBiotix Announces First Patient Dosed in Phase 2b RISE Study of EBX-102-02 in Irritable Bowel Syndrome with Constipation
EnteroBiotix’s TrIuMPH Phase 2 trial of EBX-102-02 in IBS selected as a Poster of Distinction at Digestive Disease Week 2026
EnteroBiotix’s TrIuMPH Phase 2 trial of EBX-102-02 in IBS selected as a Poster of Distinction at Digestive Disease Week 2026
EnteroBiotix Secures £19m to Initiate Phase 2b Clinical Trial for Irritable Bowel Syndrome
EnteroBiotix Secures £19m to Initiate Phase 2b Clinical Trial for Irritable Bowel Syndrome
EnteroBiotix Announces Completion of Enrolment in Phase 2a Trial Evaluating EBX-102-02 Prior to Allogeneic Stem Cell Transplantation
EnteroBiotix Announces Completion of Enrolment in Phase 2a Trial Evaluating EBX-102-02 Prior to Allogeneic Stem Cell Transplantation
EnteroBiotix announces positive Phase 2 TrIuMPH results supporting EBX-102-02 as a potential first-in-class, oral, full-spectrum microbiome therapy for irritable bowel syndrome
EnteroBiotix announces positive Phase 2 TrIuMPH results supporting EBX-102-02 as a potential first-in-class, oral, full-spectrum microbiome therapy for irritable bowel syndrome
EnteroBiotix Presents Positive Data in Liver Cirrhosis at EASL 2025
EnteroBiotix Presents Positive Data in Liver Cirrhosis at EASL 2025
EnteroBiotix Presents Positive IBS-C Data at Digestive Disease Week® 2025
EnteroBiotix Presents Positive IBS-C Data at Digestive Disease Week® 2025
EnteroBiotix to Present Results from Phase 1b trial in Liver Cirrhosis at EASL Congress 2025
EnteroBiotix to Present Results from Phase 1b trial in Liver Cirrhosis at EASL Congress 2025
EnteroBiotix Announces Oral Presentation of Phase 2a IBS-C Results at Digestive Disease Week® 2025
EnteroBiotix Announces Oral Presentation of Phase 2a IBS-C Results at Digestive Disease Week® 2025
EnteroBiotix Announces Positive Topline Phase 2a Results with EBX-102-02, a Potential First-in-Class Treatment for Irritable Bowel Syndrome (IBS)
EnteroBiotix Announces Positive Topline Phase 2a Results with EBX-102-02, a Potential First-in-Class Treatment for Irritable Bowel Syndrome (IBS)

EBX in the news

News
EnteroBiotix article features in Medicine Maker
EnteroBiotix article features in Medicine Maker
EnteroBiotix article features in the European Biopharmaceutical Review
EnteroBiotix article features in the European Biopharmaceutical Review
EnteroBiotix CEO features in Forbes 30 under 30
EnteroBiotix CEO features in Forbes 30 under 30
EnteroBiotix CEO featured on The Pharma Letter podcast talking about mastering the microbiome
EnteroBiotix CEO featured on The Pharma Letter podcast talking about mastering the microbiome
EnteroBiotix completes new manufacturing facility focused on gut microbiome therapies
EnteroBiotix completes new manufacturing facility focused on gut microbiome therapies
EnteroBiotix secures $21.5M series A to advance microbiome drug pipeline
EnteroBiotix secures $21.5M series A to advance microbiome drug pipeline
EnteroBiotix raises more than $21M in Series A
EnteroBiotix raises more than $21M in Series A

 Find out more about our donor programme. Visit Number2.org